VACCINI | VAXZEVRIA - AZD1222 | OXFORD/ASTRAZENECA
- New England Journal of Medicine, 9 aprile 2021 | “Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination”
- New England Journal of Medicine, 16 marzo 2021 | “Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant”
- AIFA, 15 marzo 2021 | “Sospensione precauzionale del vaccino AstraZeneca”
- The Lancet, 19 febbraio 2021 | “Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials”
- The Lancet, 19 febbraio 2021 | “Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials”
- AIFA, 30 gennaio 2021 | Autorizzato il vaccino Astrazeneca
- AIFA, 29 gennaio 2021 | EMA raccomanda l’autorizzazione di COVID-19 Vaccine AstraZeneca nell’UE
- AIFA, 31 dicembre 2020 | “Aggiornamento sulla revisione ciclica del vaccino COVID-19 di AstraZeneca”
- The Lancet, 18 novembre 2020 | “Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial”
- The Lancet, 20 luglio 2020 | “ Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial”